drug · small molecule
trabectedin
Marketedupdated 3mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 10 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying trabectedin
- phase3A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- phase2Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
- phase2Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
- phase2Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
- phase2SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
- phase1Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
- phase2Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
- phase2Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 7, 2028
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 7, 2028patentUS 8895557*PED1.9y
- Jan 7, 2028formulationUS 88955571.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that